Treatment Options

A Systematic Review of Tumor Treating Fields Therapy for High-Grade GliomasBookmark

Research paper from Journal of Neuro-Oncology curated by Editor in Chief George Lundberg, MD, who notes: 

Tumor-treating fields (TTF) is a type of cancer treatment that uses alternating electric pulses. Its use for adults with high-grade gliomas remains controversial, and as outlined in this academic review paper, more high-quality research is needed.

Go to full paper published in Journal of Neuro-Oncology.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Clinical Challenges: Platinum-Resistant Ovarian CancerBookmark

Article from MedPage Today curated by Editor in Chief George Lundberg, MD, who notes: 

Chemotherapy in the form of a single drug (as opposed to a combination of drugs) remains the best treatment for relapsed, platinum-resistant, serous, epithelial ovarian cancer. However, clinical trials are exploring new targeted therapy and immunotherapy options for this disease.

Go to full article published by MedPage Today.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

FDA Approves Merck’s Keytruda, Foundation Medicine CDx for TMB-High Solid TumorsBookmark

Article from GenomeWeb curated by Editor in Chief George Lundberg, MD, who notes: 

The U.S. Food and Drug Administration (FDA) has approved the drug pembrolizumab (brand name Keytruda) for solid tumors based solely on whether they have a high tumor mutational burden—a high number of changes in the DNA of the cancer cells.

Go to full article published by GenomeWeb.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Expert on Emergence of Osimertinib, New Discoveries in Lung Cancer CareBookmark

Article from Cancer Network curated by Editor in Chief George Lundberg, MD, who notes: 

The drug osimertinib (brand name Tagrisso) is beneficial as an adjuvant therapy—treatment given in addition to tumor-removal surgery—for patients with stage IB–IIIA non-small cell lung cancer (NSCLC) that has a mutation in the EGFR gene.

Go to full article published by Cancer Network.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

FDA Grants Rare Pediatric Disease Designation to ONC201 for the Treatment of H3 K27M-Mutant GliomaBookmark

Press release from Oncoceutics curated by Executive Director Erika Vial Monteverdi.

The U.S. Food and Drug Administration has granted Rare Pediatric Disease Designation to the drug ONC201 for treating a type of brain tumor known as “H3 K27M-mutant glioma,” which is primarily found in children. Alongside the Musella Foundation For Brain Tumor Research & Information, Inc, and the company xCures, Cancer Commons has been supporting this program to help patients in need.

Go to full article published by Novocure on Business Wire.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Diffuse Midline GliomasBookmark

Curated by Editor in Chief George Lundberg, MD, who notes:

China NMPA Approves Optune for the Treatment of Newly Diagnosed and Recurrent GlioblastomaBookmark

Press release from Novocure curated by Editor in Chief George Lundberg, MD, who notes: 

Chinese doctors managing one the most difficult tumors to treat, glioblastoma (GBM), now have another approved option, Optune, after favorable clinical trial results. The method has been previously approved by the U.S. Food and Drug Administration.

Go to full article published by Novocure on Business Wire.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian CancerBookmark

Article from The ASCO Post curated by Editor in Chief George Lundberg, MD, who notes: 

Go to full article published by The ASCO Post.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.

FDA Approves Frontline Atezolizumab for PD-L1–High NSCLCBookmark

Article from OncLive curated by Editor in Chief George Lundberg, MD, who notes:

The U.S. Food and Drug Administration (FDA) has approved another new drug for people with metastatic non-small cell lung cancer (NSCLC) tumors that have high levels of a protein called PD-L1.

Go to full article published by OncLive.

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.